OSAKA, Japan, May 14, 2026

日本大阪，2026年5月14日

– Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, PhD; hereinafter “Shionogi”) announced that results from its global, double-blind, randomized, placebo-controlled Phase 3 study,

– 盐野义制药株式会社（总部：日本大阪；首席执行官：手代木功博士；以下简称“盐野义”）宣布了其全球性、双盲、随机、安慰剂对照的3期研究结果，

SCORPIO-PEP, were published in the

天蝎座-PEP，已发布在

New England Journal of Medicine

新英格兰医学杂志

. A five-day course of ensitrelvir significantly reduced the risk of symptomatic COVID-19 by 67% in individuals following exposure to an infected individual through Day 10 compared to placebo.

恩司特韦五天疗程显著降低了与感染者接触后第10天内出现症状的COVID-19风险，相比安慰剂组减少了67%。

1

1

Among participants in the primary analysis population (n=2,041) who received ensitrelvir, 2.9% developed symptomatic COVID-19, compared to 9.0% of those who received placebo through Day 10 (risk ratio: 0.33; 95% confidence interval [CI]: 0.22-0.49; p<0.0001).

在主要分析人群（n=2,041）中，接受恩司特韦的参与者中有2.9%出现了有症状的COVID-19，而接受安慰剂的参与者在第10天时这一比例为9.0%（风险比：0.33；95%置信区间[CI]：0.22-0.49；p<0.0001）。

1,2

1,2

In a prespecified subgroup analysis of participants with one or more risk factors for severe disease, a 76% reduction in relative risk for symptomatic COVID-19 was observed with ensitrelvir through day 10, compared to placebo.

在对有一个或多个重症风险因素的参与者进行预先指定的亚组分析中，与安慰剂相比，恩司特韦在第10天时对有症状的COVID-19的相对风险降低了76%。

1

1

In this subgroup, 2.4% of participants who received ensitrelvir (9/382) developed symptomatic COVID-19 compared to 9.9% who received placebo (37/374) (risk ratio: 0.24; 95% CI: 0.12-0.49).

在此子组中，接受恩司特韦治疗的参与者中有2.4%（9/382）出现症状性COVID-19，而接受安慰剂的参与者中有9.9%（37/374）出现症状性COVID-19（风险比：0.24；95%置信区间：0.12-0.49）。

1

1

“Ensitrelvir works to inhibit viral replication, helping protect people who have been exposed to COVID-19 from becoming sick. In this study, people taking ensitrelvir within 72 hours after household exposure were three times less likely to develop COVID-19 compared with those given placebo,” said Frederick Hayden, MD, professor emeritus of clinical virology and professor emeritus of medicine, University of Virginia School of Medicine.

“恩赛特韦能够抑制病毒复制，帮助保护那些接触过COVID-19的人不致生病。在这项研究中，与接受安慰剂的人相比，在家庭接触后72小时内服用恩赛特韦的人患COVID-19的可能性降低了三倍，”弗吉尼亚大学医学院临床病毒学名誉教授及医学名誉教授Frederick Hayden博士说道。

“These first, clearly positive results with an oral antiviral underscore ensitrelvir’s potential to protect a range of individuals from COVID-19, including those at higher risk of severe disease and potentially in other settings.” .

“这些初步的、明确积极的口服抗病毒药物结果突显了恩赛特雷韦在保护各类人群免受 COVID-19 侵害方面的潜力，包括那些重症高风险人群以及可能在其他情况下的应用。”

In the SCORPIO-PEP study, ensitrelvir was generally well tolerated, with similar rates of adverse events across groups (15.1% in the ensitrelvir group (n=1,190) and 15.5% in the placebo group (n=1,187)).

在 SCORPIO-PEP 研究中，恩司特韦通常耐受性良好，各组的不良事件发生率相似（恩司特韦组 (n=1,190) 为 15.1%，安慰剂组 (n=1,187) 为 15.5%）。

1

1

The most common treatment-emergent adverse events (≥1%) were headache, diarrhea, nasopharyngitis, cough, fatigue and influenza.

最常见的治疗中出现的不良事件（≥1%）为头痛、腹泻、鼻咽炎、咳嗽、疲劳和流感。

3

3

There were no reports of altered taste (dysgeusia) attributed to ensitrelvir in the trial.

试验中没有报告显示因使用 ensitrelvir 而导致味觉改变（味觉障碍）。

1

1

Future SARS-CoV-2 transmission and impact are unpredictable, with the potential for surges and emergence of new variants, such as the heavily mutated Omicron subvariant BA.3.2, nicknamed “Cicada” now circulating in at least 25 U.S. states.

未来 SARS-CoV-2 的传播和影响无法预测，可能会出现激增和新变种，例如目前在美国至少 25 个州流行的、被称为“蝉”的高度变异的奥密克戎亚变种 BA.3.2。

4,5,6,7

4,5,6,7

COVID-19 can become severe, and even if mild or moderate, it can exacerbate or worsen chronic conditions or lead to the onset of new ones, including long COVID.

COVID-19可能会变得严重，即使病情轻微或中度，它也可能加剧或恶化慢性疾病，或者导致新的疾病发生，包括长期COVID。

8,9,10,11,12

8、9、10、11、12

Following exposure to COVID-19, an effective way to avoid its potentially serious and long-term complications is to block viral replication, which helps prevent the development of the disease.

在接触新冠病毒后，避免其可能带来的严重且长期并发症的有效方法是阻断病毒复制，这有助于防止疾病的发展。

13,14,15,16

13,14,15,16

There are currently no approved oral antiviral therapies to prevent COVID-19 following exposure.

目前尚无经批准的口服抗病毒疗法用于预防接触后的COVID-19。

17,18

17，18

Other COVID-19 antivirals approved for treatment are taken after illness has developed and the immune cascade has begun.

其他已批准用于治疗的新冠抗病毒药物是在疾病发展和免疫级联反应开始后服用的。

19

19

“Ensitrelvir offers a potential new approach to help prevent COVID-19 after exposure. By preventing COVID-19, people can avoid not only potentially serious consequences of acute disease, but also the risk of exacerbating pre-existing conditions or acquiring new conditions, such as long COVID. Ensitrelvir cuts the chances of developing COVID-19 by two-thirds, which is substantial, particularly in households where the risk of spread is high,” said Aeron Hurt, PhD, vice president, global medical science, Shionogi.

“Ensitrelvir 提供了一种潜在的新方法，可以帮助在接触新冠病毒后预防感染。通过预防 COVID-19，人们不仅可以避免急性疾病可能带来的严重后果，还可以降低加重原有疾病或患上新疾病（如长期新冠）的风险。Ensitrelvir 将感染 COVID-19 的几率降低了三分之二，这一效果非常显著，尤其是在家庭内部传播风险较高的情况下。” ——盐野义制药全球医学科学副总裁 Aeron Hurt 博士

“Shionogi’s deep expertise in antivirals has changed the way we treat and prevent other viral infections, including influenza and HIV, and there is an opportunity to do the same with COVID-19. Ensitrelvir has the potential to be the first oral antiviral to help prevent COVID-19 after exposure.”.

“盐野义在抗病毒领域的深厚专业知识已经改变了我们治疗和预防其他病毒感染（包括流感和艾滋病毒）的方式，并且在COVID-19方面也有同样的机会。恩赛特韦有潜力成为首个在接触后帮助预防COVID-19的口服抗病毒药物。”

About SCORPIO-PEP

关于SCORPIO-PEP

The global, double-blind, randomized, placebo-controlled Phase 3 study, SCORPIO-PEP, assessed the safety and efficacy of ensitrelvir as post-exposure prophylaxis. The study included 2,387 study participants aged 12 years and older with a negative local screening test for SARS-CoV-2 infection and no symptoms at the time of enrollment, who were exposed to a person living in their household with symptomatic COVID-19.

全球性、双盲、随机、安慰剂对照的3期研究SCORPIO-PEP评估了ensitrelvir作为暴露后预防用药的安全性和有效性。该研究纳入了2387名12岁及以上的研究参与者，他们在入组时新冠病毒感染的本地筛查测试呈阴性且无症状，但曾接触过与其同住的有症状新冠患者。

The primary analysis included 2,041 household contact participants with a central laboratory-confirmed negative SARS-CoV-2 test..

主要分析包括2041名家庭接触者参与者，其中央实验室确认的SARS-CoV-2检测结果为阴性。

The trial was conducted from June 2023–September 2024. More than 98% of household contacts tested positive for SARS-CoV-2 N and/or S antibodies, indicating that nearly all had evidence previous SARS-CoV-2 infection or vaccination, or both.

试验于 2023 年 6 月至 2024 年 9 月进行。超过 98% 的家庭接触者对 SARS-CoV-2 N 和/或 S 抗体呈阳性，表明几乎所有人均有既往 SARS-CoV-2 感染或疫苗接种或两者兼有的证据。

Study participants were randomly assigned at a 1:1 ratio to receive ensitrelvir (375 mg on day 1 and 125 mg on days 2-5) or placebo, once daily, and began treatment within 72 hours of when the household member with COVID-19 (index patient) began showing symptoms. Participants then continued ensitrelvir (125 mg) or placebo for five days.

研究参与者以1:1的比例随机分配接受恩司特韦（第1天375毫克，第2-5天125毫克）或安慰剂，每日一次，并在家中感染新冠病毒的成员（初始患者）出现症状后72小时内开始治疗。随后参与者继续服用恩司特韦（125毫克）或安慰剂，持续五天。

SCORPIO-PEP is the first and only Phase 3 study of an oral antiviral to meet the primary endpoint of preventing COVID-19 following exposure to an infected individual..

天蝎座-PEP 是第一个也是唯一一个达到口服抗病毒药物在接触感染者后预防 COVID-19 的主要终点的第三阶段研究。

About ensitrelvir

关于ensitrelvir

Ensitrelvir is a SARS-CoV-2 main protease inhibitor created through joint research between Hokkaido University and Shionogi. SARS-CoV-2 has an enzyme called the main protease, which is essential for the replication of the virus. Ensitrelvir suppresses the replication of SARS-CoV-2 by selectively inhibiting the main protease..

Ensitrelvir 是一种由北海道大学和盐野义制药共同研发的新冠病毒主蛋白酶抑制剂。新冠病毒含有一种对病毒复制至关重要的酶，称为主蛋白酶。Ensitrelvir 通过选择性抑制主蛋白酶来抑制新冠病毒的复制。

Ensitrelvir is under review by the U.S. FDA for post-exposure prophylaxis (PEP) of COVID-19, with a Prescription Drug User Fee Act (PDUFA) action date of June 16, 2026.

恩赛特韦正在接受美国FDA用于COVID-19暴露后预防（PEP）的审查，处方药使用者费用法案（PDUFA）的行动日期为2026年6月16日。

Ensitrelvir, known as XOCOVA® in Japan,

恩司特韦，日本称为XOCOVA®，

received emergency regulatory approval

收到紧急监管批准

in Japan in November 2022 and

2022年11月在日本

full approval

完全批准

in March 2024 for the treatment of COVID-19 based on

2024年3月用于治疗COVID-19基于

results

结果

from SCORPIO-SR, a Phase 3 study conducted in Asia, during the Omicron-dominant phase of the pandemic. Results from this study were

来自SCORPIO-SR，一项在亚洲进行的第三阶段研究，在疫情期间Omicron毒株占主导的阶段。这项研究的结果是

published

已发布

in

在

JAMA Network Open

JAMA网络开放

.

。

In 2025, Shionogi submitted a supplemental New Drug Application for COVID-19 treatment in pediatric patients aged 6 to under 12 years in Japan. In March 2026, XOCOVA received

2025年，盐野义制药在日本提交了针对6至12岁以下儿童的新冠治疗补充新药申请。2026年3月，XOCOVA获得批准。

approval in Japan for the prevention of COVID-19 following exposure

在日本获得暴露后预防COVID-19的批准

. Ensitrelvir is currently

恩司特韦目前

under regulatory review in Taiwan

在台湾处于监管审查之下

for post-exposure prophylaxis of COVID-19.

用于COVID-19的暴露后预防。

Ensitrelvir is an investigational drug outside of Japan. In addition, the brand name XOCOVA has not been approved for use outside of Japan and pertains only to the approved drug in Japan.

Ensitrelvir 是日本以外地区的一种试验性药物。此外，品牌名称 XOCOVA 尚未获准在日本以外地区使用，仅适用于日本已批准的药物。

About Shionogi & Co., Ltd.

关于盐野义制药株式会社

Shionogi & Co., Ltd. is a 148-year-old global, research-driven pharmaceutical company headquartered in Osaka, Japan, that is dedicated to bringing benefits to patients based on its corporate philosophy of “supplying the best possible medicine to protect the health and wellbeing of the patients we serve.” The company currently markets products in several therapeutic areas including anti-infectives, pain, CNS disorders and cardiovascular diseases.

盐野义制药株式会社是一家拥有148年历史的全球性研究驱动型制药公司，总部位于日本大阪，致力于根据其“提供尽可能好的药物来保护我们服务的患者的健康和福祉”的企业理念为患者带来益处。该公司目前在多个治疗领域销售产品，包括抗感染药、镇痛药、中枢神经系统疾病和心血管疾病。

Shionogi’s research and development currently targets two therapeutic areas: infectious diseases and diseases with unmet medical needs in pain/CNS, including Alzheimer’s disease, oncology, rare diseases, and sleep apnea. For more information on Shionogi & Co., Ltd., please visit .

盐野义制药目前的研发目标锁定在两个治疗领域：传染病和在疼痛/中枢神经系统方面存在未满足医疗需求的疾病，包括阿尔茨海默病、肿瘤学、罕见病和睡眠呼吸暂停。如需更多关于盐野义制药株式会社的信息，请访问。

https://www.shionogi.com/global/en

https://www.shionogi.com/global/zh

.

。

Forward-Looking Statements

前瞻性声明

This announcement contains forward-looking statements. These statements are based on expectations in light of the information currently available, assumptions that are subject to risks and uncertainties which could cause actual results to differ materially from these statements. Risks and uncertainties include general domestic and international economic conditions such as general industry and market conditions, and changes of interest rate and currency exchange rate.

本公告包含前瞻性陈述。这些陈述是基于当前可获得的信息和预期，而这些假设受风险和不确定性的影响，可能导致实际结果与这些陈述有重大差异。风险和不确定性包括一般国内和国际经济状况，如一般行业和市场状况，以及利率和汇率的变化。

These risks and uncertainties particularly apply with respect to product-related forward-looking statements. Product risks and uncertainties include, but are not limited to, completion and discontinuation of clinical trials; obtaining regulatory approvals; claims and concerns about product safety and efficacy; technological advances; adverse outcome of important litigation; domestic and foreign healthcare reforms and changes of laws and regulations.

这些风险和不确定性尤其适用于与产品相关的前瞻性声明。产品风险和不确定性包括但不限于：临床试验的完成和终止；获得监管批准；对产品安全性和有效性的主张和担忧；技术进步；重要诉讼的不利结果；国内外医疗改革以及法律法规的变化。

Also for existing products, there are manufacturing and marketing risks, which include, but are not limited to, inability to build production capacity to meet demand, lack of availability of raw materials and entry of competitive products. The company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise..

对于现有产品，也存在生产和营销风险，包括但不限于无法建立满足需求的生产能力、原材料供应不足以及竞争产品的进入。公司否认任何更新或修改任何前瞻性声明的意图或义务，无论是否由于新信息、未来事件或其他原因。

For Further Information, Contact:

如需更多信息，请联系：

U.S. Media:

美国媒体：

ShionogiCommunications@shionogi.com

ShionogiCommunications@shionogi.com

SHIONOGI Website Inquiry Form:

SHIONOGI网站咨询表：

https://www.shionogi.com/global/en/contact.html

https://www.shionogi.com/global/en/contact.html

Shionogi Europe Press Office:

盐野义欧洲新闻办公室：

pressoffice@shionogi.eu

pressoffice@shionogi.eu

*Literature search conducted March 2026.

*文献检索于2026年3月进行。

References:

参考文献：

1

1

Hayden FG, Shinkai M, Clark TW, et al. Ensitrelvir COVID-19 Post-exposure Prophylaxis in Household Contacts. (Publication)

Hayden FG、Shinkai M、Clark TW 等。恩司特韦对家庭接触者的新冠病毒暴露后预防。（出版物）

2

2

Hayden FG, Shinkai M, Clark TW, et al. Ensitrelvir COVID-19 Post-exposure Prophylaxis in Household Contacts. (Publication Supplement)

Hayden FG, Shinkai M, Clark TW, 等。恩司特韦对家庭接触者的COVID-19暴露后预防。（出版物补充）

3

3

Hayden FG, Ohmagari N, et.al. Ensitrelvir for the prevention of COVID-19 among household contacts: Key subgroup analyses of SCORPIO-PEP phase 3 study. Abstract 03159. Presented at Congress of the European Society of Clinical Microbiology and Infectious Diseases 2026.

海登 FG，大牧 N，等。恩赛特雷韦预防家庭接触者中的 COVID-19：SCORPIO-PEP 三期研究的关键亚组分析。摘要编号 03159。于2026年欧洲临床微生物学和传染病学会大会发表。

https://shionogimedical.com/s3fs/s3fs-public/2025-04/Ensitrelvir%20for%20the%20Prevention%20of%20COVID-19%20Among%20Household.pdf

https://shionogimedical.com/s3fs/s3fs-public/2025-04/恩司特韦用于预防家庭内COVID-19.pdf

.

。

4

4

Jalal H, Lee K, Burke DS. Oscillating spatiotemporal patterns of COVID-19 in the United States.

贾拉尔 H，李 K，伯克 DS。美国 COVID-19 的振荡时空模式。

Sci Rep.

科学报告

16 Sept 2024;(14):21562. DOI:

2024年9月16日；（14）：21562。DOI：

10.1038/s41598-024-72517-6

10.1038/s41598-024-72517-6

.

。

5

5

Rose EB, Paden CR, et al. Estimated COVID-19 periodicity and correlation with SARS-CoV-2 spike protein S1 antigenic diversity, United States.

罗斯 EB，帕登 CR 等。估计 COVID-19 的周期性及其与 SARS-CoV-2 刺突蛋白 S1 抗原多样性的相关性，美国。

Emerg Infect Dis

新发传染病

. 2025;31(8):1573–1579. DOI:

. 2025;31(8):1573–1579. DOI:

10.3201/eid3108.250451

10.3201/eid3108.250451

.

。

6

6

Centers for Disease Control and Prevention. Early Detection and Surveillance of the SARS-CoV-2 Variant BA.3.2 — Worldwide, November 2024–February 2026.

疾病控制与预防中心。SARS-CoV-2变异株BA.3.2的早期检测与监测——全球，2024年11月–2026年2月。

Morbidity and Mortality Weekly Report

发病率和死亡率周报

. 2026;75(10):130-137. DOI:

. 2026;75(10):130-137. DOI:

10.15585/mmwr.mm7510a1

10.15585/mmwr.mm7510a1

.

。

7

7

Rubin, R. What to know about Cicada, or BA.3.2, the latest SARS-CoV-2 variant under monitoring.

鲁宾，R. 关于最新受监测的SARS-CoV-2变种Cicada，或称BA.3.2，需要了解什么。

JAMA

《美国医学会杂志》

. 17 Apr 2026. DOI:

. 2026年4月17日. DOI:

10.1001/jama.2026.5535

10.1001/jama.2026.5535

8

8

Xie Y, Xu E, Bowe B, et al. Long-term cardiovascular outcomes of COVID-19.

谢毅，徐恩，鲍威等。COVID-19的长期心血管结局。

Nat Med

自然医学

. 7 Feb 2022;28(3): 583–590. DOI:

2022年2月7日；28（3）：583-590。DOI：

10.1038/s41591-022-01689-3

10.1038/s41591-022-01689-3

.

。

9

9

Xie Y, Xu E, Al-Aly Z. Risks of mental health outcomes in people with COVID-19: cohort study.

谢毅，徐恩，阿里-阿利 Z. 感染 COVID-19 人群的心理健康结果风险：队列研究。

BMJ

英国医学杂志

. 16 Feb 2022;376:e068993. DOI:

. 2022年2月16日；376:e068993. DOI:

10.1136/bmj-2021-068993

10.1136/bmj-2021-068993

.

。

10

10

Srivastava S, Garg I. Post-COVID-19 infection: Long-term effects on liver and kidneys.

Srivastava S，Garg I。新冠肺炎感染后：对肝脏和肾脏的长期影响。

World J Meta-Anal

世界期刊荟萃分析

. 28 Jun 2021;9(3):220–233. DOI:

. 2021年6月28日；9（3）：220-233. DOI：

10.13105/wjma.v9.i3.220

10.13105/wjma.v9.i3.220

.

。

11

11

Tenforde MW, Kim SS, Lindsell CJ, et al. Symptom duration and risk factors for delayed return to usual health among outpatients with COVID-19 in a multistate health care systems network—United States, March–June 2020.

Tenforde MW，Kim SS，Lindsell CJ 等。美国多州医疗系统网络中COVID-19门诊患者症状持续时间及延迟恢复健康的风险因素——2020年3月至6月。

Morbidity and Mortality Weekly Report

疾病发病率和死亡率每周报告

. 31 Jul 2020;69(30):993–998. DOI:

。2020年7月31日；69（30）：993-998。DOI：

10.15585/mmwr.mm6930e1

10.15585/mmwr.mm6930e1

.

。

12

12

Graham EL, Clark JR, Orban ZS, et al. Persistent neurologic symptoms and cognitive dysfunction in non-hospitalized COVID-19 “long haulers.”

格雷厄姆 EL、克拉克 JR、奥尔班 ZS 等。非住院 COVID-19 “长期症状患者”中的持续神经症状和认知功能障碍。

Ann Clin Trans Neurol

神经病学临床与转化研究年鉴

. 23 Mar 2021;8(5):1073–1085. DOI:

. 2021年3月23日；8(5):1073–1085. DOI:

10.1002/acn3.51350

10.1002/acn3.51350

.

。

13

13

Centers for Disease Control and Prevention. Preliminary estimates of COVID-19 burden for 2024–2025. 6 Feb 2026. Available at:

疾病控制与预防中心。2024-2025年COVID-19负担的初步估计。2026年2月6日发布。可用地址：

https://www.cdc.gov/covid/php/surveillance/burden-estimates.html

https://www.cdc.gov/covid/php/surveillance/burden-estimates.html

.

。

14

14

World Health Organization. Post COVID-19 condition (Long COVID). 7 Dec 2022. Available at:

世界卫生组织。新冠后遗症（长期新冠）。2022年12月7日。可用链接：

https://www.who.int/europe/news-room/fact-sheets/item/post-covid-19-condition

https://www.who.int/europe/news-room/fact-sheets/item/post-covid-19-condition

.

。

15

15

Al-Aly Z, Davis HE, McCorkell L, et al. Long COVID science, research and policy.

Al-Aly Z, Davis HE, McCorkell L, 等。长期新冠的科学、研究与政策。

Nat Med

自然医学

. 9 Aug 2024;30(8):2148–2164. DOI:

。2024年8月9日；30（8）：2148–2164。DOI：

10.1038/s41591-024-03173-6

10.1038/s41591-024-03173-6

.

。

16

16

Al-Aly Z, Topol E. Solving the puzzle of long COVID.

Al-Aly Z，Topol E. 解开长期新冠之谜。

Sci

科学

. 22 Feb 2024;383(6685):830–832. DOI:

2024年2月22日；383（6685）：830-832。DOI：

10.1126/science.adl0867

10.1126/科学.adl0867

.

。

17

17

U.S. Food and Drug Administration. FDA authorizes REGEN-COV monoclonal antibody therapy for post-exposure prophylaxis (prevention) for COVID-19. 2021. Available at:

美国食品药品监督管理局。FDA 批准 REGEN-COV 单克隆抗体疗法用于 COVID-19 的暴露后预防。2021。可用链接：

https://www.fda.gov/drugs/drug-safety-and-availability/fda-authorizes-regen-cov-monoclonal-antibody-therapy-post-exposure-prophylaxis-prevention-covid-19

https://www.fda.gov/drugs/drug-safety-and-availability/fda-authorizes-regen-cov-monoclonal-antibody-therapy-post-exposure-prophylaxis-prevention-covid-19

.

。

18

18

U.S. Food and Drug Administration. Revocation of emergency use of a drug product during the COVID-19 pandemic; availability.

美国食品药品监督管理局。在COVID-19大流行期间撤销药品的紧急使用授权；可用性。

Federal Register

联邦公报

. 2024. Available at:

. 2024. 可在以下网址获取：

https://www.federalregister.gov/documents/2024/03/11/2024-05085/revocation-of-emergency-use-of-a-drug-product-during-the-covid-19-pandemic-availability

https://www.federalregister.gov/documents/2024/03/11/2024-05085/在-covid-19-疫情期间撤销药物产品的紧急使用-可用性

.

。

19

19

Centers for Disease Control and Prevention.

疾病控制与预防中心。

COVID-19 treatments and medications

COVID-19 治疗方法和药物

. 2023. Available at:

. 2023. 可在以下位置获取：

https://www.cdc.gov/covid/treatment/index.html

https://www.cdc.gov/covid/treatment/index.html

.

。